Video Games Therapy on Balance and Cognitive Functions in Mild to Moderate Impaired Multiple Sclerosis Patients.
NCT03353974, Not applicable, Completed, University Hospital of Ferrara
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Video Games Therapy on Balance and Cognitive Functions in Mild to Moderate Impaired Multiple Sclerosis Patients. | ClinicalTrials.gov |
| NCT number | NCT03353974 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 48 participants, actual | ClinicalTrials.gov |
| Lead sponsor | University Hospital of Ferrara | ClinicalTrials.gov |
| Conditions | Multiple Sclerosis | ClinicalTrials.gov |
| Interventions | Video game therapy, Balance platform therapy | ClinicalTrials.gov |
| First posted | 2017-11-27 | ClinicalTrials.gov |
| Last updated | 2023-11-22 | ClinicalTrials.gov |
Registered outcomes 15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Timed Up and Go (TUG) test | Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up | TUG measures balance and functional mobility. | ClinicalTrials.gov |
| Secondary | Four Square Step Test (FSST) | Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up | The FSST is a timed test, intended to challenge the rapid change in direction while stepping forward, backward and sideways over a low obstacle. | ClinicalTrials.gov |
| Secondary | Functional Reach Test (FRT) | Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up | The FRT assesses the subject's stability by measuring the maximum distance an individual can reach forward while standing in a fixed position. | ClinicalTrials.gov |
| Secondary | Dynamic Gait Index (DGI) | Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up | Clinical tool to assess gait, balance and risk of fall. | ClinicalTrials.gov |
| Secondary | Modified Fatigue Impact Scale (MFIS) | Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up | Questionnaire which evaluates the perceived impact of fatigue on the subscales physical, cognitive and psychosocial functioning. | ClinicalTrials.gov |
| Secondary | Multiple Sclerosis Walking Scale-12 (MSWS-12) | Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up | This questionnaire assesses the impact of MS on walking ability. | ClinicalTrials.gov |
| Secondary | Multiple Sclerosis Impact Scale-29 (MSIS-29) | Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up | This is an health-rated quality of life questionnaire that assesses the impact of MS on physical and psychological functions. | ClinicalTrials.gov |
| Secondary | Beck Depression Inventory-Second Edition (BDI-II) | Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up | This is a 21-item self-report instrument that serves to assess depression severity | ClinicalTrials.gov |
| Secondary | State Trait Anxiety Inventory (STAI-Y) | Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up | STAI-Y is an easy-to-use and interpretative tool to detect and measure anxiety. | ClinicalTrials.gov |
| Secondary | Go-No Go - Test of Attentional Performance T.A.P. | Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up | Go-No Go task examine the specific capacity to suppress an inadequate reaction. | ClinicalTrials.gov |
| Secondary | Test of Attentional Performance T.A.P. | Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up | In this task divided attention can be explored with computerized "dual-task" test where two stimuli (visual and acoustic) are required simultaneously | ClinicalTrials.gov |
| Secondary | Stroop Color-Word Test (SCWT) | Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up | The SCWT explores sustained attention and some aspects of executive function. | ClinicalTrials.gov |
| Secondary | Symbol Digit Modalities Test (SDMT) | Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up | The SDMT consists of orally substituting a number for a pseudorandom sequence of geometric figures as quickly as possible for testing executive functions. | ClinicalTrials.gov |
| Secondary | Instrumented Basic Balance Evaluation (IBBE) | Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up | Force platform measurement are used as objective markers of subjects' balance ability. | ClinicalTrials.gov |
| Secondary | Instrumented Dual Task (IDT) | Changes from baseline to end of treatment (4 weeks), following changes after 12 weeks follow up | Dual cognitive-motor tasks are often used in clinical practice to evaluate the interaction between patients' cognitive and motor ability . | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 34675018 | DERIVED | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Go/No-Go Task | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Symbol Coding | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)